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1642Objective: Vein graft failure rates resulting from adverse graft remodeling remain high with no effective ther-
apy. The mineralocorticoid receptor (MR) plays a role in pathologic arterial remodeling. We demonstrated re-
cently that the MR is upregulated in venous tissues after grafting and hypothesized that MR inhibition would
reduce vein graft remodeling.
Methods: Reverse transcription polymerase chain reaction and immunoblotting were used to examine the ex-
pression of the MR and other components of the renin–angiotensin–aldosterone system in human vein and pri-
mary human saphenous vein smooth muscle cells (HSVSMC). Adenoviral reporter gene assays were used to
explore MR transcriptional activity in HSVSMC. The effect of MR inhibition on vein graft remodeling
in vivo was characterized in a mouse vein graft model.
Results:Messenger RNAs encoding the MR, 11-b-hydroxysteroid dehydrogenase 2, angiotensin type 1 recep-
tor, and the angiotensin-converting enzyme are expressed in whole HSVSMC. MR and 11-b-hydroxysteroid de-
hydrogenase 2 protein expression is confirmed, and MR-dependent transcriptional regulation is demonstrated at
physiologic aldosterone concentrations in HSVSMC. Treatment of mice with theMR antagonist spironolactone,
at doses that do not lower blood pressure (20 mg/kg per day), reduces maximal vein graft intima–media thick-
ness by 68%, with an associated reduction in graft inflammatory cell infiltration and fibrosis.
Conclusions:MR is expressed in human venous tissue and cells and modulates gene expression in HSVSMC in
response to physiologic aldosterone concentrations. In vivo, MR inhibition reduces vein graft thickening and
inflammation. These preclinical data support the potential to use MR antagonists as novel treatments to preserve
vein graft patency. (J Thorac Cardiovasc Surg 2013;145:1642-9)Supplemental material is available online.
Bypass surgery remains an important therapeutic option for
patients with arterial occlusive disease; however, vein graft
failure rates resulting from adverse graft remodeling remain
high with no effective therapy. Veins placed in the arterial
circulation undergo adaptive remodeling with rapid smooth
muscle cell (SMC) hyperplasia, thereby reducing wall
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The Journal of Thoracic and Cardiovascular Surdedifferentiation from a contractile phenotype into a syn-
thetic state that proliferates and secretes cytokines and
growth factors, which contribute to a robust inflammatory
response.2 This process leads to histologic changes resem-
bling those seen in arterial atherosclerosis, including the
development of inflamed focal lesions that can occlude
blood flow or rupture, leading to thrombus formation.3,4
The pathologic changes found in failed vein graft
specimens removed from patients undergoing corrective
reintervention have also been demonstrated in mouse
models of vein grafting, providing a small-animal model
to test potential therapies.3,5
The mineralocorticoid receptor (MR) is a hormone-
activated transcription factor that modulates gene expres-
sion when activated.6 The MR is the terminal component
of the renin–angiotensin–aldosterone system (RAAS) that
is activated in response to hypotension, resulting in produc-
tion of angiotensin II by the angiotensin-converting enzyme
(ACE), which promotes adrenal gland aldosterone release
via angiotensin type 1 receptors (AT1Rs). The MR is acti-
vated by the steroid hormones aldosterone or cortisol
with equal affinity, but the presence of the cortisol-
inactivating enzyme 11-b-hydroxysteroid dehydrogenase-
2 (11bHSD2) confers aldosterone specificity for the MR in
tissues where they are coexpressed.6 The MR is most wellgery c June 2013
Abbreviations and Acronyms
11bHSD2 ¼ 11-b-hydroxysteroid dehydrogenase-2
ACE ¼ angiotensin-converting enzyme
AT1R ¼ angiotensin type 1 receptor
Ct ¼ cycle threshold
DMEM ¼ Dulbecco’s Modified Eagle Medium
H&E ¼ hematoxylin & eosin
HSVSMC ¼ human saphenous vein smooth muscle
cell
IVC ¼ inferior vena cava
MR ¼ mineralocorticoid receptor
mRNA ¼ messenger ribonucleic acid
RAAS ¼ renin–angiotensin–aldosterone system
SMC ¼ smooth muscle cell
Ehsan et al Evolving Technology/Basic Sciencestudied in the kidney,where it raises blood pressurewhen ac-
tivated by enhancing renal sodium absorption.6 However,
our group and others have demonstrated that arterial SMC
and endothelial cells express the MR, which contributes to
arterial remodeling with enhanced vascular inflammation,
fibrosis, and SMC hyperplasia.6-8 We demonstrated
recently that both the MR and 11bHSD2 are upregulated
after grafting in a rabbit vein graft model and also in
failing saphenous vein grafts explanted from humans,
suggesting a potential role for venous MR in vein graft
failure.9 Here, we characterize further the expression and
function of the RAAS in human venous tissue and cells
and explore the role ofMRantagonism as a potential therapy
to prevent adverse remodeling in a mouse model of vein
grafting.E
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Reagents and Cell Lines
Aldosterone and spironolactone (Sigma, St Louis, Mo) were resus-
pended in dimethylsulfoxide, diluted in Dulbecco’s Modified Eagle Me-
dium (DMEM; Gibco, Grand Island, NY), and used at the indicated
concentrations with corresponding vehicle controls. With approval from
the Tufts institutional review board, deidentified samples of discarded hu-
man venous tissues that had been harvested endoscopically from patients
undergoing indicated coronary artery bypass graft surgery were collected.
Primary human vein SMCs were isolated from saphenous vein specimens
as described.10 For gene expression studies, primary cells were grown in
10% bovine serum (HyClone, Logan, Utah) in DMEM and were used be-
tween passages 3 and 7.
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Total RNA was isolated from cells or tissue, reverse transcribed, and
quantitative polymerase chain reaction was performed as described
previously11 using primers listed in Table E1. Genes with raw cycle thresh-
old (Ct) values of 35 cycles were considered not to be expressed. The Ct
values of expressed genes were normalized to glyceraldehyde-3-phosphate
dehydrogenase. Data are represented as the mean normalized expression
(2DCt) in RNA isolated from 4 independent tissue or cell sources each
analyzed in duplicate.The Journal of Thoracic and CarImmunoblotting
Cell lysates were prepared as described previously.7 Cell lysates (1 mL
control HEK293 cell lysate overexpressing MR or 11bHSD2, 30 mL dena-
tured human saphenous vein SMC (HSVSMC) supernatant for MR immu-
noblots, and 50 mL of the resuspended pellet for 11bHSD2 immunoblots)
were separated by 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis, transferred to 0.45-mm nitrocellulose membranes,
immunoblotted with monoclonal antibodies raised against the unique
MR N-terminus (generous gift from Celso Gomez-Sanchez)12 or the
11bHSD2 C-terminal catalytic domain (Alpha Diagnostic International,
San Antonio, Tex), and visualized by standard chemiluminescence tech-
niques as described previously.7
Luciferase Assay
HSVSMC were serum starved in DMEM for 24 hours, then infected
with an adenovirus containing a fused mineralocorticoid responsive ele-
ment–firefly luciferase construct9 at a multiplicity of infection of 200, as
described previously.7 After infection, cells were grown in DMEM with
5% charcoal-stripped fetal bovine serum (Atlanta Biologicals, Lawrence-
ville, Ga) containing vehicle or the indicated hormones for 18 hours.
Luciferase activity was determined as described previously.7 Luciferase
units for each sample were normalized to the value obtained for the
vehicle-treated sample for a given experiment to generate the reported
fold-change in luciferase activity (n ¼ 3-4 independent experiments,
each in duplicate).
Mouse Inferior Vena Cava-to-Aorta Vein Graft
Model
Animals were handled in accordance with National Institutes of Health
standards, and all procedures were approved by the Tufts Medical Center
Institutional Animal Care and Use Committee. The inferior vena cava
(IVC) from a donor male 12- to 16-week-old inbred, wild-type C57BL6
mouse (Jackson Laboratories, Bar Harbor, Me) was grafted into the abdom-
inal aorta of an equivalent recipient mouse as described previously.5 After
verifying sufficient blood flow through the graft by in vivo microscopy, re-
cipient mice were randomized to receive a spironolactone (20 mg/kg per
day)- or placebo-releasing drug pellet (Innovative Research of America,
Sarasota, Fla; n ¼ 8 per treatment). We and others have demonstrated
that at this low dose, spironolactone does not change mouse systolic or di-
astolic tail cuff blood pressure (data not shown13). Early graft thrombosis
(within 24 hours) requiring euthanasia occurred in some mice, with a sur-
vival rate at 4 weeks that was unchanged between the 2 treatment groups.
After 4 weeks, the grafted and native IVCwere harvested (n¼ 4 per group),
fixed in 10% neutral-buffered formalin, and embedded in paraffin for sub-
sequent immunohistochemical analyses.10
Immunohistochemistry
Sections of embedded vessels were collected at 200-mm intervals
covering the central 1.6 mm of the graft, yielding 8 sections spanning
approximately 60% of the total graft length. Serial parallel sections
were stained with hematoxylin & eosin (H&E), trichrome stain, and
smooth muscle-specific alpha actin antibody as described.14 The area
of the vessel intima and media was quantified from H&E-stained sections
using ImagePro 6.2 software (Media Cybernetics, Rockville, Md). Vessel
extracellular matrix content was quantified in trichrome-stained sections
and expressed as the absolute intima–media extracellular matrix area. For
mononuclear and polymorphonuclear cell quantification, nuclei were
counted manually in H&E-stained sections. Serial sections stained with
an anti–smooth muscle alpha actin antibody were used to count the num-
ber of actin-positive cells and actin-positive area within the grafted
vessel wall. All histological quantifications were performed by a treat-
ment-blinded investigator and reported for the section with the thickest
intima–media area for each mouse.diovascular Surgery c Volume 145, Number 6 1643
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Values are reported as mean  standard error of the mean. Statistical
comparisons were made by t test, 1- or 2-factor analysis of variance
when appropriate with the Student-Newman-Keuls or Mann-Whitney
post test using SigmaPlot 11.0 (Systat Software, Chicago, Ill). A value of
P<.05 was considered significant.0.00001
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FIGURE 1. Expression of renin–angiotensin–aldosterone system
(RAAS) components in human saphenous vein tissue and smooth muscle
cells (HSVSMC). A, Quantitative reverse transcription–polymerase chain
reaction was conducted to identify RAAS gene messenger RNA
(mRNA) isolated from human saphenous vein (white bars) and HSVSMC
(black bars). n ¼ 4. B, Immunoblots on HSVSMC lysates with antibody
specific for mineralocorticoid receptor (MR; top) and 11-b-hydroxysteroid
dehydrogenase-2 (11bHSD2; bottom) protein. Lysate from HEK293 cells
transfected with empty plasmid () or with plasmid that expresses MR or
11bHSD2 (þ) serve as negative and positive controls, respectively. ND,
Not detected; GR, glucocorticoid receptor; ACE, angiotensin-convertingRESULTS
Expression of RAAS Genes in Human Saphenous
Vein Tissue and SMCs
Total RNA was isolated from human saphenous vein
samples collected from the operating room and from low-
passage primary cultured HSVSMC (n ¼ 4 of each), and
quantitative reverse transcription–polymerase chain reac-
tion was performed using primers specific to genes encod-
ing components of the RAAS. Figure 1, A demonstrates
that the MR, glucocorticoid receptor, 11bHSD2, ACE-1,
and AT1Rmessenger RNAs (mRNAs) are indeed expressed
in human saphenous vein tissue and HSVSMC from male
and female patients with varied cardiac risk factors under-
going cardiac bypass surgery, whereas renin and aldoste-
rone synthase mRNA are not detected. MR and 11bHSD2
protein expression was examined in cell lysates from pri-
mary cultured HSVSMC. Immunoblotting revealed the
characteristic 107-kDa MR protein band and the 41-kDa
11bHSD2 protein band, as demonstrated by comparison
with overexpressed proteins (positive [þ] and negative []
control lanes on the same immunoblot; Figure 1, B). These
data support the potential for MR to be activated by aldoste-
rone in HSVSMC.enzyme; AT1R, angiotensin type 1 receptor; AS, aldosterone synthase;
MR, mineralocorticoid receptor.
Endogenous MR in HSVSMC Is Activated
Transcriptionally by Physiologic Aldosterone
Concentrations
Steroid hormones modulate cellular physiology by bind-
ing to steroid receptors to regulate gene expression. We
have demonstrated previously that MR in HSVSMC can
modulate gene transcription when activated by pathologic
aldosterone concentrations, as seen in patients with
congestive heart failure (10 nM)6; however, most vein graft
patients have normal serum aldosterone levels (1 nM). A
sensitive adenoviral reporter of MR-mediated gene expres-
sion was used to explore the dose–response relationship of
aldosterone activation of HSVSMC MR. Gene expression
was activated by aldosterone in a dose-dependent manner
beginning at a concentration of 1 nM (Figure 2, A),
consistent with physiologic aldosterone levels15 and the
known dissociation constant of the MR for aldosterone
binding.6 Treatment of cells with aldosterone in the pres-
ence of the MR antagonist spironolactone inhibited
aldosterone-dependent transcriptional activation (Figure 2,
B), which supports that transcriptional activation by aldo-
sterone is mediated by endogenousMR in HSVSMC. These
data support the potential for MR to be activated1644 The Journal of Thoracic and Cardiovascular Surtranscriptionally in saphenous vein SMC by relevant circu-
lating aldosterone levels found in vein graft patients and
could therefore play a role in vein graft remodeling in vivo.MR Inhibition With Spironolactone Attenuates Vein
Graft Remodeling in Vivo
Using a mouse model of IVC-to-aorta interposition graft-
ing, we investigated the effects of MR inhibition on vein
graft remodeling. At the time of vein grafting, mice were
randomized to treatment with placebo or to the clinically
available MR antagonist spironolactone (20 mg/kg per
day, a dose that does not reduce blood pressure significantly
[data not shown and13]). The native (ungrafted) and grafted
IVC were harvested, and graft remodeling was character-
ized histologically after 4 weeks, a time point when signif-
icant vessel remodeling and inflammation have been
observed in multiple animal models of vein grafting5,16
and in humans.17 In both treatment groups, the grafted
IVC exhibited dramatic remodeling with pathology similar
to that seen in human vein grafts, including substantial ves-
sel thickening (Figure 3) and SMC hyperplasia (Figure 4)gery c June 2013
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FIGURE 2. Functional mineralocorticoid receptor (MR) in human saphenous vein smoothmuscle cells (HSVSMC). Primary HSVSMCwere infected with
an adenovirus containing a mineralocorticoid-inducible response element–luciferase transcriptional reporter. A, Infected cells were treated with increasing
doses of aldosterone (Aldo), and Aldo-induced changes in luciferase activity were measured. B, Cells were treated with 10 nM Aldo and/or the MR antag-
onist spironolactone (Spiro). Dash indicates reagents not added. *P<.05 versus vehicle. yP<.05 versus 10 nM Aldo.
Ehsan et al Evolving Technology/Basic Sciencewhen compared with the native IVC. Spironolactone treat-
ment resulted in a 68% reduction in the maximal graft in-
tima–media thickness (Figure 3). The degree of SMC
hyperplasia was quantified in sections stained with smooth
muscle-specific actin antibody. Despite decreased totalFIGURE 3. Mineralocorticoid receptor antagonism reduces vein graft thicken
the native inferior vena cava (IVC) and throughout the grafted IVC from placebo
imal (left) to distal (right) orientation. Scale bar¼ 0.1 mm. B, Quantification of
boxes) in A from placebo- (white bar) and Spiro-treated (black bar) mice. *P<
The Journal of Thoracic and Cargraft thickness, there is no difference in the degree of
SMC hyperplasia as measured by smooth muscle actin-
positive area and the number of SMCs in vein grafts from
spironolactone-treated mice (Figure 4). Vein graft fibrosis
was also quantified in trichrome-stained sections from theing in mice. A, Representative hematoxylin & eosin–stained sections from
- and spironolactone (Spiro)-treated mice. Images are arranged from prox-
the intima–media area of the section with maximal vessel thickness (black
.05 versus placebo.
diovascular Surgery c Volume 145, Number 6 1645
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FIGURE 4. Vein graft smooth muscle cell (SMC) hyperplasia with mineralocorticoid receptor antagonism. Immunohistochemical staining of native and
grafted inferior vena cava (IVC) sections using SMC-specific a-actin antibody. Actin-positive area and nuclei count in SMC actin-positive regions are quan-
tified in vein sections from spironolactone-treated animals (black bars) and placebo-treated animals (white bars). Scale bar ¼ 0.1 mm. *P<.05 versus
placebo.
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duced the vessel intima–media collagen area by 53%
(Figure 5, A). These data support that MR antagonism
does not alter the extent of SMC hyperplasia in response
to grafting, but rather attenuates the degree of fibrosis in
the grafted veins. The number of inflammatory cells in
the grafted vessel wall was quantified by examining
serial sections under high magnification (403). Inflamma-
tory cells were counted based on nuclear morphology on
H&E-stained sections, revealing a 3-fold reduction in poly-
morphonuclear inflammatory cells in the grafts of animals
treated with spironolactone, with no difference in the num-
ber of mononuclear inflammatory cells (Figure 5, B).
DISCUSSION
In this study, we demonstrate that human venous tissue
expresses MR and other components of the RAAS, and
that MR in HSVSMC is active transcriptionally at physio-
logically relevant aldosterone concentrations. Moreover,
in a mouse model of vein grafting, MR antagonism with
the clinically available drug spironolactone prevents vein
graft remodeling with significant reductions in maximal
graft thickening, total graft fibrosis, and graft inflammation.1646 The Journal of Thoracic and Cardiovascular SurThe responsiveness of the vasculature to aldosterone has
been controversial and relatively unexplored in the venous
system. Here we demonstrate that the RAAS components
MR, glucocorticoid receptor, 11bHSD2, ACE, and AT1R
are all expressed in human saphenous vein and cultured
HSVSMC isolated from individuals with diverse cardiac
risk factors. The finding that 11bHSD2 mRNA and protein
are expressed in HSVSMC supports that human venous
SMCs, like arterial SMCs,7 also have the potential to re-
spond to aldosterone, although the potential for cortisol to
activate venous SMC MR under certain circumstances can-
not be ruled out. In addition, MR and 11bHSD2 are upregu-
lated in failed human vein grafts, suggesting that
aldosterone-mediated MR signaling may be enhanced dur-
ing graft failure.9 The role of local vascular aldosterone pro-
duction remains controversial.6 The absence of aldosterone
synthase mRNA in venous tissue and cells supports that MR
activation in venous cells, as in arterial SMC,7 is likely de-
pendent on extravascular sources of aldosterone. We have
demonstrated previously that angiotensin II, acting via the
AT1R, can also activate MR directly in human arterial
SMCs and that aldosterone can regulate AT1R expression
in saphenous veins.7,9 Thus, the presence of AT1Rgery c June 2013
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FIGURE 5. Inhibition of the mineralocorticoid receptor reduces vein graft fibrosis and inflammation. A, Quantification of vein graft trichrome-stained
collagen area on the thickest sections from placebo- (white bars) and spironolactone (Spiro)-treated (black bars) mice. Scale bar ¼ 0.1 mm. B, Quantifi-
cation of inflammatory cells in high-power (403) images of hematoxylin & eosin–stained sections of placebo- and spironolactone-treated animals. Rep-
resentative mononuclear (MN) cells are indicated by white arrows; polymorphonuclear (PMN) cells are indicated by white asterisks. Scale bar ¼ 0.02
mm. *P<.05 versus placebo.
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potential for bidirectional cross-talk between MR and
AT1R in the human vein as well.6
In this study, endogenous MR in human venous SMCs
was activated transcriptionally by concentrations of aldo-
sterone similar to those found in normal patient popula-
tions.15 Epidemiologic studies demonstrate that, in
individuals with vascular disease, higher levels of aldoste-
rone—even within the normal range—are associated with
a nearly 2.5-fold increase in cardiovascular ischemia and
a 3.5-fold increase in cardiovascular death.18 In arterial
SMCs and endothelial cells, aldosterone and the MR upre-
gulate pathways that promote adverse vascular remodeling
in response to injury, including medial hypertrophy and ath-
erosclerosis.6,8 Given that the biologic processes leading to
adverse vein graft remodeling are much like those seen in
arterial injury,3,8 these findings support that MR activation
could play an important role in vein graft remodeling.
Multiple mouse vein graft models have been developed.
Here we used the IVC-to-abdominal aorta technique origi-
nally described by Salzberg and coworkers5 because the he-
modynamics of the end-to-end anastomoses, ratio of graft to
host vessel diameters, lack of foreign external support ma-
terials, and remodeling processes are all similar to current
human surgical techniques and pathologies.5,19 Using this
model, we demonstrate that administration of the MR
antagonist spironolactone reduces focal vein graftThe Journal of Thoracic and Carthickening dramatically. This focal pattern of remodeling
is particularly disruptive to hemodynamic flow and is the
most frequent cause of vein graft failure.20 The vasculopro-
tective effects of RAAS blockade are traditionally thought
to be the result of reduced blood pressures achieved through
inhibition of renal MR. However, numerous clinical trials of
RAAS antagonists have demonstrated cardiovascular bene-
fits that exceed the modest reduction in blood pressure.6,21
Consistent with previous findings,13 the dose of spironolac-
tone used did not change blood pressure significantly (data
not shown), supporting a direct protective effect of MR
antagonism on the grafted vein. The decreased vessel thick-
ness observed with spironolactone treatment is accompa-
nied by a concomitant reduction in vessel fibrosis.
Aldosterone promotes arterial fibrosis in response to in-
jury6,8 and the MR regulates directly a number of
profibrotic genes in SMCs and arteries, including type 1
and type 3 collagens and connective tissue growth
factor.7,11 The role of these vascular MR-regulated fibrosis
genes in vein graft remodeling and fibrosis warrants further
exploration.
The source and type of cells that account for wall thick-
ening as a result of vein graft remodeling is not clear, al-
though prior studies have focused on SMC hyperplasia as
the predominant contributor. Here, we observed no
MR-mediated changes in graft SMC hyperplasia or cell
number; rather, we saw that reduced graft thicknessdiovascular Surgery c Volume 145, Number 6 1647
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part, by decreased inflammatory cell infiltration. Clinical
and animal studies also support a role for inflammation in
early vein graft remodeling. In patients undergoing lower
extremity bypass surgery, markers of systemic inflamma-
tion (C-reactive protein) correlate with the degree of vein
graft remodeling after 1 month.17 Consistent with this find-
ing, blockade of monocyte chemoattractant factor, a proin-
flammatory molecule upregulated by aldosterone in the
setting of vascular disease,6 inhibits vein graft remodeling
in a canine model.22 We conclude that MR-mediated vascu-
lar inflammation may be an important component of vein
graft remodeling. It has also been shown that AT1R block-
ade attenuates arterial remodeling by reducing inflamma-
tory-like progenitor cells.23 Thus, inflammatory cell
recruitment may be a common mechanism in RAAS-
mediated vein graft remodeling.
This study has several important limitations that suggest
future studies. Althoughwe demonstrate a significant reduc-
tion in vein graft thickening, fibrosis, and inflammation in
spironolactone-treated mice, this study is, necessarily, de-
scriptive and further studies are needed to explore the mo-
lecular mechanisms involved in these processes. The use
of a mouse vein graft model with a transplanted donor
vein will allow for future studies using genetically altered
donor and recipient mice to investigate the mechanisms. Al-
thoughMRantagonist drugs are generallywell tolerated, the
overall effort, potential risk, and cost of doing a human ran-
domized, controlled trial are not insubstantial, and thus ad-
ditional data would be helpful to justify such a trial. This
would include additional preclinical studies of MR antago-
nism in larger animalmodels such as the rabbit or pigmodel,
as well as testing of a more selectiveMR antagonist, such as
eplerenone, to support the mechanism further. Finally, we
demonstrate expression of MR in human saphenous vein
specimens from patients with diverse clinical characteristics
and cardiac risk factors; however, future studies would re-
quire a much larger sample size to identify specific clinical
characteristics that correlate with venousMR activation and
would thus identify the patients most likely to benefit from
MR antagonist therapy in a clinical trial.
In summary, vein graft surgery for obstructive coronary
or peripheral vascular disease remains an evidenced-based
treatment for a large patient population but is limited by
a lack of graft durability with no effective therapy.5,24,25
This study implicates the MR in vein graft pathobiology
in humans and demonstrates beneficial effects on graft
remodeling using the clinically available MR antagonist
in a mouse model. This study provides the first preclinical
data in support of a clinical trial using an MR antagonist,
started at the time of arterial bypass surgery using
a venous conduit, to improve graft patency. Although
further studies are needed to characterize the mechanism
of MR-mediated vein graft remodeling and the patient1648 The Journal of Thoracic and Cardiovascular Surpopulations most likely to benefit from MR inhibition, the
long history of safety and cardiovascular benefit afforded
by MR antagonists in patients with cardiovascular disease
supports great potential for clinical translation of this study.
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TABLE E1. Primer sequences used in this study
Primer Sequence (50 to 30)
GAPDH forward TGG GTG TGA ACC ATG AGA AG
GAPDH reverse GCTAAG CAG TTG GTG GTG C
MR forward CCG GCT TTG ATG GTA ACT GT
MR reverse CCC CAA CAATAG CAG AGG AA
ATR1 forward ACT TTG CCA CTATGG GCT GTC
ATR1 reverse GTA CAG GTT GAA ACT GAC GCT
ACE1 forward ACC TCA ACC TGC ATG CCTAC
ACE1 reverse AGG GCA CCA CCA AGT CATAG
AS forward ACC TGG AGATGC ACC AGA C
AS reverse GGC CCATTC AAC AAG AAC ACG
ATNG forward GCT GCT GAG AAG ATT GAC AGG
ATNG reverse TTT GCC TTA CCT TGG AAG TGG
GR forward CTG TCG CTT CTC AAT CAG ACT C
GR reverse GCATTG CTTACT GAG CCT TTT G
11bHSD2 forward TCT GGT TTT GGC AAG GAG AC
11bHSD2 reverse GCC AAA GAA ATT CAC CTC CA
Renin forward CCG TGATCC TCA CCA ACTACA
Renin reverse GCA CCC AAA CAT TGG ACG AAC
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase;MR, mineralocorticoid recep-
tor; ATR1, angiotensin type 1 receptor; ACE1, angiotensin-converting enzyme type 1;
AS, aldosterone synthase; ATNG, angiotensinogen; GR, glucocorticoid receptor;
11bHSD2, 11-b-hydroxysteroid dehydrogenase-2.
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